SCHEDULE: Frazier Life Sciences Funds Update Aura Biosciences Stake
Beneficial Ownership Disclosure
Frazier Life Sciences entities filed an amended Schedule 13G, disclosing their beneficial ownership in Aura Biosciences, Inc. as of December 31, 2025.
Summary
- Frazier Life Sciences Public Fund, L.P. beneficially owns 4,032,060 shares of Aura Biosciences, Inc. common stock, representing 6.3% of the class.
- Frazier Life Sciences X, L.P. beneficially owns 128,520 shares of Aura Biosciences, Inc. common stock, representing 0.2% of the class.
- Frazier Life Sciences XI, L.P. beneficially owns 342,210 shares of Aura Biosciences, Inc. common stock, representing 0.5% of the class.
- Frazier Life Sciences XII, L.P. beneficially owns 597,210 shares of Aura Biosciences, Inc. common stock, representing 0.9% of the class.
- The reported percentages are calculated based on 63,503,269 shares of Common Stock outstanding on November 10, 2025.
- The reporting persons also hold prefunded warrants to acquire additional shares, subject to a 9.99% beneficial ownership limitation upon exercise.
- The securities were not acquired or held for the purpose of changing or influencing the control of Aura Biosciences, Inc.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, providing a factual update on institutional ownership without indicating any significant positive or negative developments for Aura Biosciences.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that Schedule 13G filings are routine disclosures by passive institutional investors, indicating their ownership stake in a public company. This filing confirms Frazier Life Sciences' continued significant, but passive, investment in Aura Biosciences, a common practice for venture capital or private equity funds that invest in public companies, particularly in the biotechnology sector.
Stakeholder Impact
- Shareholders are informed of the beneficial ownership stakes held by Frazier Life Sciences entities, providing transparency regarding significant institutional holdings.
Key Dates
| Date | Description |
|---|---|
| 2025-11-10 | Date on which 63,503,269 shares of Common Stock were outstanding, as reported in Aura Biosciences' Form 10-Q. |
| 2025-11-13 | Date Aura Biosciences, Inc. filed its Quarterly Report on Form 10-Q with the SEC. |
| 2025-12-31 | Date of event which requires the filing of this Schedule 13G statement. |
| 2026-01-27 | Date a Power of Attorney for James N. Topper and Patrick J. Heron was filed with the SEC. |
| 2026-02-13 | Date of the Joint Filing Agreement and the signing of the Schedule 13G statement. |
Keywords
Aura Biosciences, Frazier Life Sciences, Schedule 13G, beneficial ownership, common stock, institutional investor, biotechnology, equity stake, SEC filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.